Bladder cancer and benign prostatic hyperplasia have been two very common diseases among the elderly men, especially with the aging of the population in the world. We have designed a study to investigate the clinical effect of interventional therapy for plasmakinetic resection of the prostate and plasmakinetic resection of the bladder, which is called "BPSC" (The bladder cancer and benign prostatic hyperplasia study in Chinese population). The BPSC is not only a specific study, it is made up of many studies. In this article, we introduced the research background, source, name, study framework, study management and further direction of BPSC project. We hope this process will contribute to the growth of the database through sharing data and enriching the evidence of bladder cancer and benign prostatic hyperplasia in the Chinese population, thereby finally improving the accessibility of these important findings for doctors, researchers, and patients.
Journal of evidence-based medicine. 2018 Feb [Epub]
Xian-Tao Zeng, Tong-Zu Liu, Kan Gong, Da-Lin He, Xing-Huan Wang, BPSC investigators
Department of Urology, Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Department of Evidence-Based Medicine and Clinical Epidemiology, The Second Clinical College of Wuhan University, Center for Evidence-Based and Translational Medicine, Wuhan University, The Endourological Clinical Research Medical Center of Hubei Province, Wuhan, Hubei, P.R. China., Department of Urology, National Urological Cancer Center, Peking University First Hospital, Institute of Urology, Peking University, Beijing, P.R. China., Department of Urology, Key Laboratory for Tumor Precision Medicine of Shaanxi Province, Oncology Research Laboratory, Key Laboratory of Environment and Genes Related to Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Ministry of Education, Xi'an, Shaanxi, P.R. China.